Mesothelin-T cell receptor engineered T cell therapy

Mesothelin-T cell receptor engineered T cell therapy is a cell therapy involving T cells genetically modified to express a T cell receptor (TCR) that specifically targets mesothelin (Msln). Mesothelin is a tumor-associated antigen that is minimally expressed in healthy tissues but overexpressed in various cancers, including ovarian cancer, making it an attractive target for immunotherapy. This therapy aims to enhance anti-tumor efficacy by directing the engineered T cells to recognize and eliminate mesothelin-expressing cancer cells. Preclinical studies in mouse models of ovarian cancer have demonstrated that combining this therapy with checkpoint blockade can significantly improve T cell function and overall animal survival.

Other names

mesothelin-specific t-cell receptor therapy